Medical Advocates

Vicriviroc (SCH 417690)
  Main Page

New and Noteworthy
Journal Data
Conference Data




 
 

ARV Investigational  Drugs Main Page Drugs Main Page Home Page      

Last Update:  March 11, 2015 
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

New and Noteworthy
     

May 2012
 

Journal Papers, Abstracts and Commentaries
     

 
A WEEK-IN REVIEW FEATURED REPORT
Vicriviroc plus optimized background therapy for treatment-experienced subjects with CCR5 HIV-1 infection:
Final results of two randomized phase III trials.
Caseiro MM, Nelson M, Diaz RS,  et al

J Infect
. 2012 May 24.

Abstract

Vicriviroc Resistance Decay and Relative Replicative Fitness in HIV-1 Clinical Isolates Under Sequential Drug Selection Pressures.
Tsibris AM, Hu Z, Paredes R,  et al

J Virol
. 2012 Apr 4.
Abstract

V3 determinants of HIV-1 escape from the CCR5 inhibitors Maraviroc and Vicriviroc.
Berro R, Klasse PJ, Moore JP, Sanders RW.

Virology
.
2012 Mar 15.
Abstract

Effect of Vicriviroc With or Without Ritonavir on Oral Contraceptive Pharmacokinetics:
A Randomized, Open-Label, Parallel-Group, Fixed-Sequence Crossover Trial in Healthy Women.
Kasserra C, Li J, March B, O'Mara E.
Clin Ther. 2011 Oct 18.
Abstract

FULL-TEXT ARTICLE
Identification and Characterization of INCB9471, an Allosteric Non-Competitive Small Molecule Antagonist of
CCR5 with Potent Inhibitory Activity against Monocyte Migration and HIV-1 Infection.
Shin N, Solomon K, Zhou N, Wang KH,  et al
J Pharmacol Exp Ther. 2011 Apr 1
Paper

'A WEEK-IN-REVIEW FEATURED REPORT
Pharmacokinetic interaction of vicriviroc with other antiretroviral agents: results from
a series of fixed-sequence and parallel-group clinical trials.
Kasserra C, O'Mara E
Clin Pharmacokinet. 2011 Apr 1;50(4):267-80.
Abstract

Pharmacokinetic interaction of vicriviroc with other antiretroviral agents: results from a series
of fixed-sequence and parallel-group clinical trials.
Kasserra C, O'Mara E.
Clin Pharmacokinet. 2011 Apr 1;50(4):267-80.
Abstract

Mapping and Characterization of Vicriviroc Resistance Mutations From HIV-1 Isolated from
Treatment-Experienced Subjects Enrolled in a Phase II Study (VICTOR-E1).
McNicholas PM, Mann PA, Lee E,  et al

J Acquir Immune Defic Syndr
. 2011 Mar 1;56(3):222-9.
Abstract
 
Vicriviroc, a new CC-chemokine receptor 5 inhibitor for treatment of HIV: properties, promises and challenges.
Lenz JC, Rockstroh JK.
Expert Opin Drug Metab Toxicol. 2010 Sep;6(9):1139-50
Abstract
 
A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal
and extracellular loop domains of drug-bound CCR5.

Tilton JC, Wilen CB, Didigu CA,  et a,l
J Virol. 2010 Oct;84(20):10863-76.
Abstract
 
Three-year safety and efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected treatment-experienced patients.
Wilkin TJ, Su Z, Krambrink A, Long J, et al
J Acquir Immune Defic Syndr. 2010 Aug 15;54(5):470-6.
Abstract

Effect of vicriviroc on the QT/corrected QT interval and central nervous system in healthy subjects.
O'Mara E, Kasserra C, Huddlestone JR, et al

Antimicrob Agents Chemother
. 2010 Jun;54(6):2448-54
Abstract

Renal insufficiency has no effect on the pharmacokinetics of vicriviroc in a ritonavir-containing
regimen.

Kasserra C, Sansone-Parsons A, Keung A,.
et al
Clin Pharmacokinet
. 2010 Jun;49(6):397-406.
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Characterization of Emergent HIV Resistance in Treatment-Naive Subjects
Enrolled in a Vicriviroc Phase 2 Trial
McNicholas P, Wei Y, Whitcomb J, et al

J Infect Dis
. 2010 Apr 7
Abstract

The Effect of Vicriviroc on the QT/QTc Interval and Central Nervous System in
Healthy Subjects.
O'Mara E, Kasserra C, Huddlestone JR, .et al
Antimicrob Agents Chemother. 2010 Mar 29
Abstract
 

FULL TEXT ARTICLE
Vicriviroc and peripheral neuropathy: results from AIDS Clinical Trials Group 5211.
Yeh TM, Evans SR, Gulick RM, Clifford DB.
HIV Clin Trials. 2010 Jan-Feb;11(1):51-8
Paper

A WEEK-IN-REVIEW FEATURED REPORT
Pharmacokinetic/Pharmacodynamic Modeling of the Antiretroviral Activity of the
CCR5 Antagonist Vicriviroc in Treatment Experienced HIV-Infected Subjects
(ACTG Protocol 5211).
Crawford KW, Li C, Keung A, Su Z, et al

J Acquir Immune Defic Syndr
. 2010 Jan 12
Abstract

A WEEK-IN REVIEW FESTERED REPORT
Vicriviroc in Combination Therapy with an Optimized Regimen for Treatment-Experienced
Subjects: 48-Week Results of the VICTOR-E1 Phase 2 Trial.
Suleiman J, Zingman BS, Diaz RS, et al
 
J Infect Dis
. 2010 Jan 11
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Vicriviroc: a CCR5 antagonist for treatment-experienced patients with HIV-1 infection.
Kümmerle T, Lehmann C, Hartmann P,
et al 
Expert Opin Investig Drugs
. 2009 Nov;18(11):1773-85
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Response to Vicriviroc in Treatment-Experienced Subjects, as Determined by an Enhanced-Sensitivity
Coreceptor Tropism Assay: Reanalysis of AIDS Clinical Trials Group A5211.
Su Z, Gulick RM, Krambrink A, et al

J Infect Dis
. 2009 Oct 29.
Abstract

Short-Term Administration of the CCR5 Antagonist Vicriviroc to Patients With HIV
and HCV Coinfection is Safe and Tolerable.
Fätkenheuer G, Hoffmann C, Slim J, et al
J Acquir Immune Defic Syndr. 2009 Oct 15
Abstract

Vicriviroc, a CCR5 receptor antagonist for the potential treatment of HIV infection.
Klibanov OM
Curr Opin Investig Drugs. 2009 Aug;10(8):845-59.
Abstract

Inefficient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR5 complex at low cell surface CCR5 densities.
Pugach P, Ray N, Klasse PJ, et al 

Virology
. 2009 Mar 19.
Abstract
 

Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy:
results of the AIDS Clinical Trials Group A5211.
Tsibris AM, Paredes R, Chadburn A,  et al

Clin Infect Dis
. 2009 Mar 1;48(5):642-9
Abstract
 
Reduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both
sensitive and drug-resistant HIV-1.
Heredia A, Latinovic O, Gallo RC,  
et al
Proc Natl Acad Sci U S A
. 2008 Dec 23;105(51):20476-81
Abstract
 
A WEEK IN REVIEW FEATURED REPORT
Phase II Study of Vicriviroc versus Efavirenz (both with Zidovudine/Lamivudine) in Treatment-Naive
Subjects with HIV-1 Infection.
Landovitz RJ, Angel JB, Hoffmann C, et al
J Infect Dis. 2008 Sep 10
Abstract
 
FULL TEXT ARTICLE
Identification of human liver cytochrome P450 enzymes involved in biotransformation of
vicriviroc, a CCR5 antagonist.

Ghosal A, Ramanathan R, Yuan Y, et al 

Drug Metab Dispos. 2007 Sep 7;
Paper

A WEEK-IN-REVIEW FEATURED REPORT
Phase 2 Study of the Safety and Efficacy of Vicriviroc, a CCR5 Inhibitor, in HIV-1-Infected,
Treatment-Experienced Patients: AIDS Clinical Trials Group 5211.

Gulick RM, Su Z, Flexner C, et al
J Infect Dis. 2007 Jul 15;196(2):304-312.
Abstra
ct

   
  Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during
14-day monotherapy in HIV-infected adults.

Schürmann D, Fätkenheuer G, Reynes J, et al
AIDS. 2007 Jun;21(10):1293-1299.
Abstract
   
  Access denied? The status of co-receptor inhibition to counter HIV entry.
Biswas P, Tambussi G, Lazzarin A.
Expert Opin Pharmacother. 2007 May;8(7):923-33.
Abstract
 
     
  HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a
clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211.

Wilkin TJ, Su Z, Kuritzkes DR, et al
Clin Infect Dis. 2007 Feb 15;44(4):591-5.
Abstract
 
   
  Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of
human immunodeficiency virus type 1.

Murga JD, Franti M, Pevear DC,et al
Antimicrob Agents Chemother. 2006 Oct;50(10):3289-96
Abstract
 
   
  FULL TEXT ARTICLE
Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent
activity against human immunodeficiency virus type 1.

Strizki JM, Tremblay C, Xu S, et al

Antimicrob Agents Chemother. 2005 Dec;49(12):4911-9
Abstract
   

Conference Reports, Abstracts,  and Posters
     

4th IAS Conference on HIV Pathogenesis, Treatment and Prevention
 
XVI International AIDS Conference
 
 
 


ARV Investigational  Drugs Main Page Drugs Main Page Home Page      

Vicriviroc